ABSTRACT
Analysis of a secondary end point of the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) found that a statin reduced the risk of venous thromboembolism (VTE) in apparently healthy people with high levels of C-reactive protein and normal levels of low-density lipoprotein cholesterol (N Engl J Med 2009; 360:1851– 1861). Still, pending more study, statins should not be substituted for proven prophylaxis and anticoagulation, especially for patients with recurrent deep venous thrombosis, hospitalized patients, postoperative patients, and other patients prone to VTE.
- © 2010 The Cleveland Clinic Foundation. All Rights Reserved.
- Alejandro Perez, MD and
- John R. Bartholomew, MD⇑
- Section of Vascular Medicine, Department of Cardiovascular Medicine, Cleveland Clinic
- Head, Section of Vascular Medicine; Professor of Medicine, Department of Cardiovascular Medicine; and Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic
- ADDRESS
: John R. Bartholomew, MD, Department of Cardiovascular Medicine, J3-5, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail barthoj{at}ccf.org.
ABSTRACT
Analysis of a secondary end point of the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) found that a statin reduced the risk of venous thromboembolism (VTE) in apparently healthy people with high levels of C-reactive protein and normal levels of low-density lipoprotein cholesterol (N Engl J Med 2009; 360:1851– 1861). Still, pending more study, statins should not be substituted for proven prophylaxis and anticoagulation, especially for patients with recurrent deep venous thrombosis, hospitalized patients, postoperative patients, and other patients prone to VTE.
- © 2010 The Cleveland Clinic Foundation. All Rights Reserved.